Raymond James Financial Services Advisors, Inc. Cara Therapeutics, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$7.45 - $13.84 $75,937 - $141,071	-10,193 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$9.94 - $12.65 $8,558 - $10,891	-861 Reduced 7.79%	10,193 $124,000
Q4 2021 Feb 08, 2022	SELL	$11.99 - $18.14 $263 - $399	-22 Reduced 0.2%	11,054 $135,000
Q3 2021 Nov 02, 2021	BUY	$11.55 - $16.06 $1,074 - $1,493	93 Added 0.85%	11,076 $171,000
Q2 2021 Aug 11, 2021	SELL	$12.38 - $29.19 $5,112 - $12,055	-413 Reduced 3.62%	10,983 $157,000
Q1 2021 May 14, 2021	SELL	$15.07 - $21.71 $1,130 - $1,628	-75 Reduced 0.65%	11,396 $247,000
Q4 2020 Feb 12, 2021	SELL	$12.72 - $16.16 $9,718 - $12,346	-764 Reduced 6.24%	11,471 $174,000
Q3 2020 Nov 04, 2020	BUY	$12.34 - $17.92 $1,641 - $2,383	133 Added 1.1%	12,235 $156,000
Q2 2020 Jul 17, 2020	BUY	$12.39 - $17.33 $5,340 - $7,469	431 Added 3.69%	12,102 $207,000
Q1 2020 Apr 21, 2020	BUY	$9.12 - $17.78 $106,439 - $207,510	11,671 New	11,671 $154,000

Others Institutions Holding CARA

# of Institutions

Shares Held

12.8M

Call Options Held

Put Options Held

Vanguard Group Inc Valley Forge, PA

2.25M
Shares

$11 Million
0.0% of portfolio
Chescapmanager LLC Baltimore, MD

1.7M
Shares

$8.31 Million
0.06% of portfolio
Farallon Capital Management LLC San Francisco, CA

1.56M
Shares

$7.59 Million
0.0% of portfolio
Disciplined Growth Investors Inc Minneapolis, MN

1.11M
Shares

$5.43 Million
0.01% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

1.11M
Shares

$5.41 Million
0.0% of portfolio

View Full List

About Cara Therapeutics, Inc.

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $262M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

More about CARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account